

1 **Systematic review and meta-analysis of interventions with dietary**
2 **supplements, including pre-, pro- and synbiotics, to reduce acute and late**
3 **gastrointestinal side effects in patients undergoing pelvic radiotherapy**

4 Benjamin Bartsch^{1#}, Chee Kin Then^{1#}, Elinor Harriss², Christiana Kartsonaki^{3,4}, Anne E.
5 Kiltie^{1*}

6 ¹Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford,
7 Oxford, UK

8 ²Bodleian Health Care Libraries, University of Oxford, Oxford, UK

9 ³Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of
10 Population Health, University of Oxford, Oxford, UK

11 ⁴Medical Research Council Population Health Research Unit (MRC PHRU) at the University of
12 Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, UK

13 #These authors contributed equally to this work.

14

15 *Corresponding author:

16 Professor Anne E Kiltie

17 Oxford Institute for Radiation Oncology

18 Department of Oncology, University of Oxford

19 Old Road Campus Research Building

20 Off Roosevelt Drive

21 Oxford OX3 7DQ

22 anne.kiltie@oncology.ox.ac.uk

23 +44 1865 617352

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **ABSTRACT**

2 **Objective:** Pelvic radiotherapy (RT) often results in toxicity to the gastrointestinal tract and
3 clinical trials have demonstrated a potentially beneficial role of dietary supplements in
4 overcoming this problem, mainly acute effects. This systematic review and meta-analysis
5 were undertaken with the aim of evaluating the efficacy of several dietary supplement
6 interventions in preventing or alleviating symptoms of gastrointestinal toxicity in patients
7 undergoing RT for a range of common pelvic malignancies.

8 **Design:** The search protocol was prospectively submitted to PROSPERO at the University of
9 York. CENTRAL, MEDLINE, EMBASE, and ClinicalTrials.gov were searched up to June 2020 for
10 randomised controlled clinical trials. Interventions included four supplement categories:
11 biotics, amino acids, poly-unsaturated fatty acids and polyphenols. Efficacy was determined
12 with reference to outcomes based on symptoms of acute gastrointestinal toxicity, including
13 diarrhoea, nausea and vomiting.

14 **Results:** Twenty-three randomised controlled trials (1919 patients) were identified in this
15 review. Compared with placebo, probiotics, synbiotics and polyphenols were significantly
16 associated with a lower risk of diarrhoea. Biotic supplements also reduced the risk of
17 moderate to severe diarrhoea and the need for anti-diarrhoeal medication. In contrast,
18 amino acid supplements had no effect on acute symptoms. There was a non-significant
19 trend for reduction in nausea and mean bowel movements per day using dietary
20 supplements.

21 **Conclusions:** Biotic supplements, especially probiotics and synbiotics, reduce acute
22 symptoms of gastrointestinal toxicity in patients undergoing pelvic radiotherapy. More
23 randomised placebo-controlled studies with larger numbers of patients are needed to

1 define specific formulations for supplement interventions that will be of greatest benefit to
2 patients.

3

4 **Summary box**

5 ***1. What is already known about this subject?***

6 Clinical trials have indicated a potentially beneficial role of dietary supplements for the
7 prevention and treatment of radiation-induced gastrointestinal symptoms.

8 ***2. What are the new findings?***

9 In this systematic review, we found biotics and polyphenols can significantly reduce the risk
10 of diarrhoea, while biotics were also associated with a lower incidence of moderate to
11 severe diarrhoea and anti-diarrhoeal medication use. Among biotic supplements, both
12 synbiotics and probiotics were found to be potentially beneficial in the prevention of
13 diarrhoea.

14 ***3. How might it impact on clinical practice in the foreseeable future?***

15 Cancer patients undergoing pelvic RT may benefit from taking biotic supplements for
16 alleviation of gastrointestinal toxicity symptoms following pelvic radiation. More
17 randomised controlled trials are required to determine the optimum formulations and
18 combinations.

19

20 **Trial registration number**

21 The study protocol was published on the PROSPERO international prospective register of
22 systematic reviews (registration number CRD42020183304).

23

- 1 **Keywords (up to 10):** amino acids, dietary supplements, meta-analysis, pelvic radiotherapy,
- 2 polyphenols, poly-unsaturated acids, prebiotics, probiotics, synbiotics, systematic review.
- 3

1 BACKGROUND

2 Radiotherapy is a major cancer treatment modality, used to treat approximately 50% of
3 patients¹. Chemoradiation (concurrent delivery of systemic chemotherapy) is generally
4 preferred over radiotherapy alone for most pelvic malignancies, including tumours of the
5 lower gastrointestinal, gynaecological and urological (with the exception of prostate cancer)
6 tracts². Over 200,000 patients in the US are treated with pelvic or abdominal radiotherapy
7 each year³. It is inevitable that normal gastrointestinal tissues are exposed to radiation
8 during pelvic radiotherapy⁴, with approximately 80% of patients developing acute
9 symptoms of radiation-induced gastrointestinal toxicity⁵. However, despite their impact on
10 patients' quality of life, no prophylactic agents for the alleviation of gastrointestinal side-
11 effects from pelvic radiation have been approved to date⁶.

12
13 The intestine is particularly radiosensitive due to the presence of rapidly replicating crypt
14 cells. Following irradiation, mucosal biopsies show evidence of extensive surface epithelial
15 atrophy, widespread disruption of absorptive and secretory activity and acute crypt
16 inflammation crypts⁷. Acute symptoms usually develop during or immediately after RT, and
17 typically improve within three months following RT⁸. The most common acute side effect is
18 diarrhoea, affecting up to 80% of all patients⁹. Other symptoms, such as abnormal stool
19 output, vomiting and gastrointestinal discomfort are also very common. Late symptoms
20 include GI bleeding, fistula, stricture and colostomy¹⁰.

21
22 Use of a dietary supplement is aimed at boosting daily intake of specific nutrients, to much
23 higher levels than obtained from the diet, to alleviate symptoms of gastrointestinal toxicity.
24 Such dietary supplements include bionics, amino acids, poly-unsaturated fatty acids (PUFAs)

1 and polyphenols. Probiotics, mainly of the *Lactobacillus* and *Bifidobacteria* genera, are live
2 microorganisms thought to produce health benefits following passage to the intestine¹¹.
3 Prebiotics are soluble or non-soluble dietary fibres, that pass undigested through the upper
4 gastrointestinal tract and are metabolised by bacteria in the colon, thus enhancing gut
5 microbiota beneficial to the host's health¹². Examples of prebiotics include inulin, fructo-
6 oligosaccharide, psyllium husk and alpha-amylase resistant starch. The use of synbiotics
7 refers to administration of a combination of prebiotics and probiotics; the presence of the
8 prebiotic enhances survival of the probiotics in the lower gastrointestinal tract.
9 Administration of probiotics, prebiotics and synbiotics can alter the gut microbiota and
10 production of key metabolites, resulting in reduced symptoms of disease and promotion of
11 well-being^{13 14}.

12

13 Amino acids, poly-unsaturated acids (PUFAs) and polyphenolic compounds have also been
14 employed in supplement intervention strategies in pelvic RT. Dietary PUFAs comprise a
15 number of molecules. Anti-inflammatory effects of the omega-6 PUFA conjugated linolenic
16 acids (CLA) are seen in inflammatory bowel disease¹⁵. Furthermore, the omega-3 fatty acids,
17 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may be capable of boosting
18 cancer cell sensitivity to drugs¹⁶. Glutamine is the most abundant amino acid with important
19 roles in support of mucosal growth and function. Evidence from animal studies confirms
20 that dietary glutamine supplementation can protect the small intestinal epithelium from
21 radiation damage¹⁷. Polyphenolic compounds extracted from plants, such as flavanols,
22 flavandiols, epigallocatechin and genistein, can also suppress or alleviate radiation-induced
23 intestinal injury. Oral administration of curcumin reversed morphological damage caused by
24 radiation treatment to rat ileal villi¹⁸. Genistein and other isoflavones extracted from soy

1 bean are similarly implicated in anti-inflammatory responses, protecting irradiated mouse
2 jejunum from adverse changes and attenuating tumour growth¹⁹.

3

4 This review tests the hypothesis that administration of oral dietary supplements for cancer
5 patients receiving pelvic radiotherapy may trigger changes in the lower gastrointestinal tract
6 which lead to a reduction in gastrointestinal toxicity. We conducted a systematic review and
7 meta-analysis of randomised controlled trials (RCTs), with the aim of determining whether
8 dietary interventions using supplements can alleviate symptoms of gastrointestinal toxicity
9 in pelvic RT patients, including diarrhoea, nausea, vomiting, flatulence/bloating and bowel
10 movement frequency.

11

1 **METHODS**

2 **Search strategy and study selection**

3 The following electronic databases were searched from inception to the search date
4 (19/06/2020) for relevant literature: Cochrane CENTRAL, Ovid Medline, Ovid Embase, and
5 ClinicalTrials.gov. The search strategies included both medical subject heading and free text
6 terms to retrieve relevant RCTs and non-randomised studies about the gastrointestinal side
7 effects in cancer patients undergoing pelvic radiotherapy, limiting to studies in humans only.
8 The full set of search strategies is available in Appendix 1 to 3, and inclusion and exclusion
9 criteria are available in the PROSPERO registration²⁰. Relevant articles were identified on
10 PubMed. Handsearching of meta-analyses, systematic reviews and papers identified studies
11 not indexed in the electronic databases used for this review. All titles and abstracts
12 retrieved by electronic searches were downloaded and duplications removed using EndNote
13 reference management software. Full-text copies of short-listed titles were obtained to
14 determine if they met the eligibility criteria. Multiple reports of the same study data were
15 eliminated, thus any original data were only included once.

16 **Data extraction**

17 Systematic data collection from included studies was conducted using a data collection form
18 designed specifically for this review. It included the following information (where available)
19 for each dataset: publication year, study design, participants (number, age distribution,
20 gender distribution, details of malignancy, details relevant to inclusion and exclusion
21 criteria), current cancer treatment (duration, fractionation and dose of RT and details of any
22 chemotherapy), intervention (type of supplement, route of intervention, formulation, dose,
23 timing with respect to RT, length of treatment and follow-up) and measured outcomes

1 (diarrhoea incidence and severity and details of other GI symptoms recorded as toxicity
2 scores, patient-reported outcome measure scores, questionnaires or interview scores).
3 Details of included studies were summarised according to the PICO model²¹. Where raw
4 data were unavailable, EndNote was used to facilitate extraction of data from charts and
5 graphs of the included studies²². Details of outcomes included time points at which they
6 were reported by study authors.

7 **Outcome assessment**

8 Different measures of treatment effects were used for dichotomous and continuous
9 outcomes, namely, risk ratio (RR) for dichotomous outcomes and the mean difference (MD)
10 between the intervention and control arms for continuous outcomes.
11 Standardised mean difference (SMD) was used to compare to compare results from studies
12 that reported the same outcomes measured on different scales.

13 **Study quality**

14 Risk of bias assessment was carried out for all studies that met the inclusion criteria, using
15 the Cochrane Risk of Bias 2 (ROB2) tool²³. The ROB2 framework investigates five domains in
16 a study, namely, the biases arising from the randomisation process, due to deviations from
17 intended interventions, due to missing outcome data, in measurement of the outcome and
18 in the selection of the reported result, with three levels of risk of bias, namely, low risk,
19 some concerns and high risk. The risk of bias across the five domains was then used to
20 derive an overall risk score. Judgements were based on assessment of statements in the
21 included studies relevant to study design. In some instances, key information was
22 incomplete, unclear or omitted from published protocols.

23 **Assessment of heterogeneity and publication bias**

1 To assess the heterogeneity, we used a chi-squared test and I^2 ^{24 25}. P values less than 0.1
2 were considered as evidence of heterogeneity. I^2 values between 0% to 40% indicated
3 ‘might not be important’, 30% to 60% indicated ‘may represent moderate heterogeneity’,
4 50% to 90% indicated ‘may represent substantial heterogeneity’ and 75% to 100% indicated
5 ‘considerable heterogeneity’ based on the Cochrane handbook²⁶. Tau-squared is the
6 estimated standard deviation of underlying effects across studies. Begg’s funnel plots were
7 used to visually assess asymmetry potentially due to publication bias.

8 **Data synthesis and statistical analysis**

9 Meta-analyses were performed to measure the effect of dietary supplements on an
10 outcome, in instances where there were three or more studies that reported the same
11 outcome. All analyses were conducted using RevMan 5.4 and R version 4.0.2 with package
12 ‘meta’^{27 28}. For dichotomous outcomes, risk ratios (RR) were estimated and were meta-
13 analysed using a random effects model using the Mantel-Haenszel (M-H) method²⁹. For
14 continuous outcomes, mean differences (MD) were estimated and were pooled using a
15 random effects model with the inverse variance (IV) method. 95% confidence intervals (CI)
16 for all estimates were calculated. For each outcome, the studies selected for quantitative
17 analysis were divided into subgroups, based on the class of intervention. Studies that met
18 inclusion criteria investigated the effect of one of the following classes: biotics, amino acids,
19 PUFAs and polyphenols. Subgroup analysis by subclass of biotic intervention (prebiotic,
20 probiotic and synbiotic) was also performed. Meta-regression by mean age, proportion of
21 male participants and sample size was used to assess whether the effects of interventions
22 on incidence of diarrhoea varied by these study characteristics.

23 **Patient and public involvement**

24 There was no patient or public involvement in the design or conduct of this study.

1 **RESULTS**

2 The search of the four primary databases identified 23,542 titles published between 1946
3 and June 2020 (search process summarised in Figure 1). After 5,825 duplications were
4 removed, a total of 17,717 entries remained. These studies were manually reviewed by title
5 and abstract and 17 met the inclusion criteria. Six further studies were identified from
6 manual searches of the reference sections of research articles. Finally, 23 studies met the
7 inclusion criteria and could be used for quantitative analysis. The effects of interventions on
8 incidence of diarrhoea did not vary by mean age, proportion of male participants or sample
9 size (Figure S1). Results of the overall and individual risk of bias assessments for each of the
10 five domains are presented in Figure S2. Fourteen studies had low risk, three studies had
11 moderate risk, and six studies had high overall risk of bias.

12

13 **Included studies and characteristics of included studies**

14 In total 23 studies involving a total of 1,919 patients met the inclusion criteria and for each
15 outcome, they were grouped by intervention category. These studies were all randomised
16 controlled trials and their characteristics are shown in the Table 1. All included studies
17 investigated the effect of dietary supplements on acute symptoms of gastrointestinal
18 toxicity. However, the individual trials differed widely in the symptoms and outcomes they
19 reported. In total, the trials included in the review reported ten different relevant
20 symptoms. For each symptom, data could be expressed according to the following three
21 outcomes: number of events, severity and time, as shown in Table S1.

22

1 **Efficacy of dietary supplements in preventing diarrhoea**

2 The meta-analysis comprising 1,625 patients showed that dietary supplements reduced the
3 risk of diarrhoea (Figure 2). The pooled risk ratio (RR) was 0.79 (95% CI: 0.66 to 0.94;
4 $P=0.007$) and there was significant heterogeneity amongst the studies ($I^2=73\%$; $P<0.001$).
5 The funnel plot for this meta-analysis (Figure 3) was largely symmetrical, implying only mild
6 publication bias in the references included. There was no evidence that heterogeneity was
7 due to mean age or sex of participants or sample size of the studies. Meta-analyses were
8 then carried out for biotic, amino acid, poly-unsaturated fatty acid and polyphenol
9 interventions.

10

11 *Efficacy of biotics in preventing diarrhoea*

12 Biotic interventions significantly reduced the risk of diarrhoea with a RR of 0.66 (95% CI:
13 0.51 to 0.86; $P=0.002$) (Figure 2). All studies, except Giralt *et al*³⁰, had a RR of less than 1,
14 suggesting the protective role of biotics against diarrhoea. The heterogeneity, I^2 , among
15 these studies was 76% ($P<0.001$), so further analysis of the subclasses of probiotics and
16 synbiotics was performed (Figure 4). The risk ratio for synbiotics (RR=0.45; 95% CI: 0.28 to
17 0.73) was lower than for probiotics (RR=0.71; 95% CI: 0.52 to 0.99). There was little
18 heterogeneity among studies on synbiotics ($I^2=0\%$; $P=0.50$).

19

20 *Efficacy of amino acids in preventing diarrhoea*

21 Amino acid interventions were not associated with risk of diarrhoea with a RR of 1.05 (95%
22 CI=0.86 to 1.29; $P=0.65$, Figure 2). Five studies which included 348 patients were used to
23 compare the incidence of diarrhoea between intervention and control groups. We found
24 that four studies had consistent results of RR which were close to 1, but only Vidal-

1 Cassariego *et al* reported a high RR of 2.75. There was high heterogeneity among studies
2 ($I^2=62\%$, $P=0.03$).

3

4 *Efficacy of poly-unsaturated fatty acids in preventing diarrhoea*

5 There was only one study in the category of poly-unsaturated fatty acids reporting the
6 outcome incidence of diarrhoea (Figure 2). This was a relatively small randomised controlled
7 trial with only 40 patients. This study had a RR of 0.63 (95% CI=0.25 to 1.58; $P=0.32$).

8

9 *Efficacy of polyphenol in preventing diarrhoea*

10 Two studies compared polyphenols and placebo among 64 patients (Figure 2). Both showed
11 that the intervention was associated with lower incidence of diarrhoea. The overall RR was
12 0.30 (95% CI=0.13 to 0.70, $P=0.005$). There was no evidence of heterogeneity between
13 these two studies ($I^2 = 0\%$, $P=0.86$).

14

1 **Efficacy of dietary supplements in preventing moderate to severe diarrhoea**

2 Efficacy of dietary supplements was assessed against moderate to severe diarrhoea, with
3 the incidence of moderate to severe diarrhoea defined as the incidence of grade 2 or higher
4 diarrhoea, based on Common Technology Criteria for Adverse Events (CTCAE)³¹ (Figure 5).
5 Dietary supplements were associated with a lower risk of moderate to severe diarrhoea
6 (RR=0.68; 95% CI: 0.48 to 0.98; P=0.04). There was high heterogeneity among studies
7 ($I^2=65%$, P=0.009). The subgroup analysis suggested that the association was mainly driven
8 by biotic interventions for which the RR was 0.49 (95% CI: 0.36 to 0.67; P<0.001), but not
9 amino acids (RR=1.05; 95% CI: 0.82 to 1.34; P=0.70).

10

11 **Efficacy of dietary supplements in preventing the use of anti-diarrhoeal medication**

12 Anti-diarrhoeal medication, such as loperamide, is often employed for patients who
13 experience diarrhoea during or after radiotherapy. Therefore, we measured the effect of
14 dietary supplements against the incidence of anti-diarrhoeal medication use (Figure 6), and
15 found that dietary supplements were associated with lower risk of anti-diarrhoeal
16 medication use in patients (RR=0.67; 95% CI: 0.47 to 0.96; P=0.03) and there was high
17 heterogeneity among studies ($I^2=62%$, P=0.01). For biotic interventions, the RR was 0.64
18 (95%CI: 0.44 to 0.92) and heterogeneity was intermediate ($I^2=45%$; P=0.11).

19

1 **Effects of dietary supplements on nausea, vomiting, flatulence/bloating and bowel**

2 **movement frequency**

3 Table 2 lists the results of meta-analysis of the other outcomes, including nausea, vomiting,
4 flatulence/bloating and bowel movement frequency. Dietary supplements tended to
5 decrease the risk of nausea (RR=0.74; 95% CI: 0.36 to 1.50; P=0.40) and the mean number of
6 bowel movements per day (mean difference=-3.88; 95% CI: -10.29 to 2.52; P<0.001). The
7 results also showed that the interventions had no effect on vomiting and flatulence/bloating
8 with relative risks of 0.99 (95% CI: 0.79 to 1.25, P=0.95) and 1.12 (95% CI: 0.59 to 2.12;
9 P=0.72) respectively.

10

1 DISCUSSION

2 In this review, 23 randomised controlled trials met inclusion criteria for quantitative
3 analysis. Risk of bias assessment was conducted for each of these studies. Meta-analyses
4 were carried out for seven of these outcomes. These showed that dietary supplements are
5 effective in reducing the risk of diarrhoea, experiencing moderate to severe diarrhoea and
6 anti-diarrhoeal medication use. Subgroup analysis showed that biotic supplements and
7 polyphenols were effective in reducing the risk of these outcomes, but amino acids were
8 ineffective. Among the subclasses of biotic interventions, both probiotic and synbiotic
9 supplements were shown to be effective in reducing the risk of diarrhoea. Taken together,
10 these results indicate that biotic supplements can reduce the risk of acute diarrhoea and the
11 severity of diarrhoea in patients undergoing pelvic radiotherapy.

12 There are important differences within and among the intervention groups regarding the
13 administration of the dietary supplements. This includes amount, timing and composition of
14 the supplement. Biotics represent a diverse range of interventions, including prebiotic,
15 probiotic and synbiotic interventions. Probiotic and synbiotic interventions can be
16 administered as a single strain/species of bacteria or a mixture of different strains/species.
17 Since little is known their interactions with the gut microbiota³², it is difficult to directly
18 compare the included trials. For the included studies, dose and choice of strains were likely
19 based on empirical observations of perceived benefits to lower gastrointestinal tract health
20 in other settings. For example, there is a history of treating inflammatory bowel disease using
21 bacteria with well-established dosage and strain parameters. Even within a bacterial genus,
22 biological activities are strain-specific. For example, *Lactobacillus casei* has a different
23 functional repertoire to other *Lactobacillus* strains³³, making a comparison with studies using

1 *L. acidophilus* or *L. rhamnosus* difficult. This hampers interpretation of results of using a
2 mixture of different strains. Delia *et al* used a cocktail of eight strains, including four strains
3 of *Lactobacilli*, three strains of *Bifidobacterium*, and *Streptococcus salivarius*³⁴.

4 Polyphenol interventions are complicated in several respects. Firstly, they are administered
5 as plant extracts, rather than a single purified active agent. Secondly, polyphenols are subject
6 to chemical modification in the small intestine³⁵ and limited bioavailability can be a problem.
7 Conversely, the amino acid interventions in this review are all based on pure glutamine, with
8 a comparatively narrow range of doses administered (8g - 45g/day). This standardisation
9 should enable high levels of comparability between trials in this intervention category. The
10 studies investigating PUFA interventions were based on omega-6 CLA or omega-3 fatty acids
11 supplements. Only two studies in this intervention category met inclusion criteria, as many
12 such trials investigate symptoms of radiation-induced cachexia, including weight and skeletal
13 muscle loss³⁶.

14 Our study is the only reported meta-analysis that investigates the efficacy of four different
15 classes of dietary supplements on acute symptoms of gastrointestinal toxicity. Most previous
16 meta-analyses investigated only a single class of dietary supplement. This review includes
17 more studies (23) and patients (1,919) than other published reviews, increasing confidence
18 in the quantitative analysis. Several meta-analyses have been conducted for probiotic and
19 synbiotic supplements over the last decade, but the category of prebiotics has not yet been
20 analysed. Therefore, the inclusion of prebiotics in this review is another key distinguishing
21 feature. The previous meta-analyses investigating the effects of biotic supplements on acute
22 symptoms of gastrointestinal toxicity are listed in Table S2. Overall, the trials included in each
23 meta-analysis are largely identical. Where different selections were made, this is mainly due

1 to variations in search strategy and the statistical methods used. A Cochrane systematic
2 review has also investigated the efficacy of interventions, including radiotherapy techniques
3 and pharmacological and non-pharmacological interventions, on acute and late adverse
4 gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers⁴. Compared to their
5 study of non-pharmacological interventions, including dietary interventions, probiotics,
6 glutamine, counselling, and protein supplements, our focused approach showed that the
7 beneficial effects mainly came from the probiotics and synbiotics. Also, the focus of the
8 Cochrane review was on prevention, rather than treatment, of acute symptoms of
9 gastrointestinal toxicity, an important difference to our review. Additionally, their search was
10 only updated to November 2017; our search to June 2020 included three more recent studies
11 of biotic supplements (224 patients) and one study focusing on PUFA supplements (40
12 patients). Currently, there are no published meta-analyses that investigate the effect of PUFA
13 or polyphenol supplements on acute symptoms of gastrointestinal toxicity, and two included
14 studies of polyphenols suggested that they are beneficial in preventing diarrhoea. One
15 analysis investigating amino acid supplements (glutamine) was identified³⁷ but rejected
16 because of different endpoints used. The authors included 13 RCTs investigating acute
17 symptoms of radiation enteritis, with the following outcomes, abdominal cramping, blood in
18 bowel movement and tenesmus. The researchers found that amino acid supplements were
19 not effective in improving symptoms. This finding is consistent with the result of this review
20 that amino acid supplements are ineffective in improving acute symptoms of gastrointestinal
21 toxicity.

22 A strength of our meta-analysis is that the data relate to patients undergoing pelvic
23 radiotherapy. They are not derived from cell lines or animal model systems. A further strength
24 is that the trials are based on direct measurements of the symptoms of gastrointestinal

1 toxicity, rather than less direct measures of effect, such as immunological, biochemical or
2 histological markers. Therefore, the findings of this review can be directly applied to clinical
3 practice. However, patient-related factors of low numbers (<40) of participants in 26% of
4 included studies represent a weakness in the statistical treatment of data sets, resulting in
5 wider confidence intervals. Most data were derived from single-centre trials, thus limiting the
6 ability to recruit larger numbers of patients. Furthermore, the baseline heterogeneity of the
7 patient cohorts is high, as it is not possible to subdivide patients into meaningfully
8 representative sub-groups in terms of age, sex, lifestyle-related factors, co-morbidities and
9 type of cancer.

10 The underlying protective effects of dietary supplements against GI toxicities may be
11 mediated as shown in Figure 7. A direct effect on the intestinal immune environment
12 following intake of specific dietary agents may lead to anti-inflammatory changes that
13 alleviate gastrointestinal toxicity. There may also be an indirect effect, whereby the above
14 immunomodulatory actions are developed in response to changes in the gut microbiota and
15 their metabolites, particularly SCFAs.

16 In terms of probiotics, these can act in three beneficial ways. Firstly, their presence may
17 down-regulate epithelial apoptosis and reduce inflammatory activity of the digestive tract,
18 possibly involving intact signalling of TLR-2, MyD88 and COX-2³⁸. Secondly, in the presence of
19 dietary fibre, probiotics produce the SCFA butyrate. Butyrate is implicated in the reduction of
20 mucosal inflammation and promotion of epithelial repair following injury. Thirdly, probiotics
21 may provide resistance against infection of the damaged mucosa by pathogens. The scientific
22 consensus is that two classes of mechanisms are involved³⁹, namely direct and indirect effects.
23 Direct effects involve competition between commensal and pathogenic bacteria for the same
24 ecological niche. This competition comprises competition for nutrients and production of

1 antimicrobial peptides and toxins⁴⁰. By contrast, indirect effects involve improvement in
2 intestinal mucosal function and stimulation of the innate and adaptive immune systems by
3 commensal bacteria⁴¹.

4 In our meta-analysis, two studies demonstrated that polyphenols reduced the risk of
5 diarrhoea with an overall RR of 0.30 (95% CI=0.13 to 0.70; P=0.005). In line with this finding,
6 polyphenols have anti-oxidant and anti-inflammatory effects in human⁴². As anti-oxidants,
7 polyphenols reduce oxidative damage by preventing the formation of reactive oxygen species
8 (ROS) and reactive nitrogen species (RNS), and by preventing the generation of these
9 species⁴³. In this way, polyphenols protect tissues against oxidative stress from ROS and RNS
10 which are both products of radiotherapy⁴⁴. It is important to acknowledge that polyphenols
11 also have other important properties, such as anti-histamine, anti-bacterial and anti-viral
12 effects. We can speculate that the mechanisms underlying these effects are similar to those
13 responsible for the anti-oxidant and anti-inflammatory effects, with possibly overlap.

14 This review aimed to investigate the effect of dietary supplements on acute and late
15 symptoms, but there were no studies reporting on late side effects among included studies.
16 Chronic symptoms of gastrointestinal toxicity typically emerge a few months to years
17 following irradiation and occur in most of the intestinal compartments⁴⁵. The prevalence of
18 chronic symptoms is reported to be between 5 and 15%⁴⁶ and can result in potentially fatal
19 complications such as fistulation, sepsis and perforation of the colon^{4,35}. Due to
20 improvements in pelvic cancer treatment, the number of cancer survivors is increasing.
21 Consequently, more patients are potentially at risk of chronic symptoms of gastrointestinal
22 toxicity. However, improvements in pelvic cancer treatment, such as the use of image guided
23 radiotherapy, have in turn resulted in a decrease in chronic radiation effects⁴⁷. The

1 pathophysiology of chronic effects is more complicated than acute effects⁴⁸. Evidence from
2 clinical studies suggests that acute and chronic effects are linked, with the risk of developing
3 late effects greater in patients that have developed acute effects (consequential late
4 effects)⁴⁹⁻⁵¹. Consistent with this finding, a systematic review that investigated the
5 relationship between acute and late gastrointestinal toxicity after RT for prostate cancer
6 concluded that acute GI toxicity may be predictive of high risk of developing late effects⁵¹.
7 Taken together, the evidence suggests that dietary supplements could ameliorate chronic
8 symptoms of gastrointestinal toxicity in two ways: directly, by minimising the
9 pathophysiology underlying chronic effects, including differentiation of mitotic fibroblasts
10 into post-mitotic fibroblasts, and indirectly, by reducing the magnitude of acute symptoms
11 and the resulting consequential late effects.

1 **CONCLUSION**

2 Findings from our systematic review and meta-analysis suggest that biotic supplements,
3 specifically probiotics and synbiotics, are effective in reducing the risk and severity of acute
4 symptoms of gastrointestinal toxicity caused by pelvic radiotherapy. The data also broadly
5 confirm that they are safe to use.

6

1 **DECLARATIONS**

2 **Acknowledgements**

3 N/A

4 **Funding**

5 This work was funded by Cancer Research UK Programme grant C5255/A23755. The funding
6 body had no role in the design of the study, collection, analysis, interpretation of data or in
7 writing the manuscript.

8 **Authors' contributions**

9 BB performed the title/abstract selection, data extraction, interpretation of the data, risk of
10 bias assessment and drafted the manuscript. CKT reviewed the title/abstract selection,
11 performed the analysis, and did the risk of bias assessment. EH ran the search strategy
12 through the databases and clinical trials registry. CK performed meta-regression and
13 reviewed the results of statistical analysis. AEK conceived the study, supervised the work,
14 and revised the manuscript. All authors critically reviewed the manuscript and approved the
15 final version.

16 **Competing interests**

17 The authors declare that they have no competing interests.

18 **Ethics Approval and Consent to Participate**

19 N/A

20

1 REFERENCES

- 2 1. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. *Nat*
3 *Rev Cancer* 2011;11(4):239-53.
- 4 2. Morris KA, Haboubi NY. Pelvic radiation therapy: Between delight and disaster. *World J*
5 *Gastrointest Surg* 2015;7(11):279-88.
- 6 3. Frazzoni L, La Marca M, Guido A, et al. Pelvic radiation disease: Updates on treatment
7 options. *World J Clin Oncol* 2015;6(6):272-80.
- 8 4. Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse
9 gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. *Cochrane*
10 *Database Syst Rev* 2018;1:CD012529.
- 11 5. Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any
12 importance? *Gut* 2005;54(8):1051-4.
- 13 6. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of
14 gastrointestinal mucositis in cancer patients. *Support Care Cancer* 2013;21(1):313-
15 26.
- 16 7. Larsen A, Bjorge B, Klementsens B, et al. Time patterns of changes in biomarkers,
17 symptoms and histopathology during pelvic radiotherapy. *Acta Oncol*
18 2007;46(5):639-50.
- 19 8. Stacey R, Green JT. Radiation-induced small bowel disease: latest developments and
20 clinical guidance. *Ther Adv Chronic Dis* 2014;5(1):15-29.
- 21 9. Visich KL, Yeo TP. The prophylactic use of probiotics in the prevention of radiation
22 therapy-induced diarrhea. *Clin J Oncol Nurs* 2010;4(14):467-73.
- 23 10. Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy
24 for prostate cancer. *Eur Urol* 2011;60(5):908-16.
- 25 11. Fijan S. Microorganisms with claimed probiotic properties: an overview of recent
26 literature. *Int J Environ Res Public Health* 2014;11(5):4745-67.
- 27 12. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific
28 Association for Probiotics and Prebiotics consensus statement on the scope and
29 appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*
30 2014;11(8):506-14.
- 31 13. Pineiro M, Asp NG, Reid G, et al. FAO Technical meeting on prebiotics. *J Clin*
32 *Gastroenterol* 2008;42 Suppl 3 Pt 2:S156-9.
- 33 14. Dinan TG, Cryan JF. The impact of gut microbiota on brain and behaviour: implications
34 for psychiatry. *Curr Opin Clin Nutr Metab Care* 2015;18(6):552-8.
- 35 15. Bassaganya-Riera J, Hontecillas R. Dietary conjugated linoleic acid and n-3
36 polyunsaturated fatty acids in inflammatory bowel disease. *Curr Opin Clin Nutr*
37 *Metab Care* 2010;13(5):569-73.
- 38 16. Hajjaji N, Bougnoux P. Selective sensitization of tumors to chemotherapy by marine-
39 derived lipids: a review. *Cancer Treat Rev* 2013;39(5):473-88.
- 40 17. Jensen JC, Schaefer R, Nwokedi E, et al. Prevention of chronic radiation enteropathy by
41 dietary glutamine. *Ann Surg Oncol* 1994;1(2):157-63.
- 42 18. Akpolat M, Kanter M, Uzal MC. Protective effects of curcumin against gamma radiation-
43 induced ileal mucosal damage. *Arch Toxicol* 2009;83(6):609-17.
- 44 19. Son TG, Gong EJ, Bae MJ, et al. Protective effect of genistein on radiation-induced
45 intestinal injury in tumor bearing mice. *BMC Complement Altern Med* 2013;13:103.

- 1 20. Kiltie A, Bartsch B, Then CK, et al. Systematic review and meta-analysis of interventions
2 with dietary supplements, including pre-, pro- and synbiotics, to reduce acute and
3 late gastrointestinal side effects in patients undergoing pelvic radiotherapy:
4 PROSPERO; 2020 [Available from:
5 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=183304.
6
- 7 21. Richardson WS, Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to
8 evidence-based decisions. *ACP J Club* 1995;123(3):A12-3.
- 9 22. EndNote [program]. EndNote X9 version. Philadelphia, PA: Clarivate, 2013.
- 10 23. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in
11 randomised trials. *BMJ* 2019;366:l4898.
- 12 24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*
13 2003;327(7414):557-60.
- 14 25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
15 2002;21(11):1539-58.
- 16 26. JPT H, J T, J C, et al. Cochrane Handbook for Systematic Reviews of Interventions:
17 Cochrane, 2019.
- 18 27. Review Manager (RevMan) [program]. Version 5.4 version. Copenhagen: The Nordic
19 Cochrane Centre: The Cochrane Collaboration, 2014.
- 20 28. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical
21 tutorial. *Evid Based Ment Health* 2019;22(4):153-60.
- 22 29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective
23 studies of disease. *J Natl Cancer Inst* 1959;22(4):719-48.
- 24 30. Giralt J, Regadera JP, Verges R, et al. Effects of probiotic *Lactobacillus casei* DN-114 001
25 in prevention of radiation-induced diarrhea: Results from multicenter, randomized,
26 placebo-controlled nutritional trial. *Int J Radiat Oncol* 2008;71(4):1213-19.
- 27 31. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In: SERVICES
28 USDOHAH, ed.: National Cancer Institute, National Institutes of Health, 2017.
- 29 32. Coyte KZ, Schluter J, Foster KR. The ecology of the microbiome: Networks, competition,
30 and stability. *Science* 2015;350(6261):663-6.
- 31 33. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut
32 mucosal barrier: successful strains and future challenges. *Antonie Van Leeuwenhoek*
33 1996;70(2-4):347-58.
- 34 34. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-
35 induced diarrhea. *World J Gastroentero* 2007;13(6):912-15.
- 36 35. Marin L, Miguelez EM, Villar CJ, et al. Bioavailability of Dietary Polyphenols and Gut
37 Microbiota Metabolism: Antimicrobial Properties. *Biomed Res Int* 2015;2015
- 38 36. Aredes MA, da Camara AO, de Paula NS, et al. Efficacy of omega-3 supplementation on
39 nutritional status, skeletal muscle, and chemoradiotherapy toxicity in cervical cancer
40 patients: A randomized, triple-blind, clinical trial conducted in a middle-income
41 country. *Nutrition* 2019;67-68:110528.
- 42 37. Cao DD, Xu HL, Xu M, et al. Therapeutic role of glutamine in management of radiation
43 enteritis: a meta-analysis of 13 randomized controlled trials. *Oncotarget*
44 2017;8(18):30595-605.
- 45 38. Ciorba MA, Riehl TE, Rao MS, et al. *Lactobacillus* probiotic protects intestinal epithelium
46 from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. *Gut*
2012;61(6):829-38.

- 1 39. Sassone-Corsi M, Raffatellu M. No Vacancy: How Beneficial Microbes Cooperate with
2 Immunity To Provide Colonization Resistance to Pathogens. *J Immunol*
3 2015;194(9):4081-87.
- 4 40. Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization
5 resistance, and enteric pathogens. *Immunol Rev* 2017;279(1):90-105.
- 6 41. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal
7 pathogens. *Nat Rev Immunol* 2013;13(11):790-801.
- 8 42. Ogawa K, Hirose S, Nagaoka S, et al. Interaction between Tea Polyphenols and Bile Acid
9 Inhibits Micellar Cholesterol Solubility. *J Agric Food Chem* 2016;64(1):204-9.
- 10 43. Hussain T, Tan B, Yin Y, et al. Oxidative Stress and Inflammation: What Polyphenols Can
11 Do for Us? *Oxid Med Cell Longev* 2016;2016:7432797.
- 12 44. Gupta SC, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species
13 for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and
14 therapy. *Antioxid Redox Signal* 2012;16(11):1295-322.
- 15 45. Shah V, Lyford G, Gores G, et al. Nitric oxide in gastrointestinal health and disease.
16 *Gastroenterology* 2004;126(3):903-13.
- 17 46. Olcina MM, Giaccia AJ. Reducing radiation-induced gastrointestinal toxicity - the role of
18 the PHD/HIF axis. *Journal of Clinical Investigation* 2016;126(10):3708-15.
- 19 47. Murray J, Griffin C, Gulliford S, et al. A randomised assessment of image guided
20 radiotherapy within a phase 3 trial of conventional or hypofractionated high dose
21 intensity modulated radiotherapy for prostate cancer. *Radiother Oncol* 2020;142:62-
22 71.
- 23 48. Dorr W. Radiobiology of tissue reactions. *Ann ICRP* 2015;44(1 Suppl):58-68.
- 24 49. Bourne RG, Kearsley JH, Grove WD, et al. The Relationship between Early and Late
25 Gastrointestinal Complications of Radiation-Therapy for Carcinoma of the Cervix. *Int*
26 *J Radiat Oncol* 1983;9(10):1445-50.
- 27 50. Wang CJ, Leung SW, Chen HC, et al. The correlation of acute toxicity and late rectal
28 injury in radiotherapy for cervical carcinoma: Evidence suggestive of consequential
29 late effect (CQLE). *Int J Radiat Oncol* 1998;40(1):85-91.
- 30 51. Peach MS, Showalter TN, Ohri N. Systematic Review of the Relationship between Acute
31 and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer. *Prostate*
32 *Cancer* 2015;2015
- 33 52. Sasidharan BK, Ramadass B, Viswanathan PN, et al. A phase 2 randomized controlled
34 trial of oral resistant starch supplements in the prevention of acute radiation
35 proctitis in patients treated for cervical cancer. *J Cancer Res Ther* 2019;15(6):1383-
36 91.
- 37 53. Linn YH, Thu KK, Win NHH. Effect of Probiotics for the Prevention of Acute Radiation-
38 Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind
39 Placebo-Controlled Study. *Probiotics Antimicro* 2019;11(2):638-47.
- 40 54. de Loera-Rodriguez LH, Ortiz GG, Rivero-Moragrega P, et al. Effect of symbiotic
41 supplementation on fecal calprotectin levels and lactic acid bacteria, Bifidobacteria,
42 Escherichia coli and Salmonella DNA in patients with cervical cancer. *Nutr Hosp*
43 2018;35(6):1394-400.
- 44 55. Mansouri-Tehrani HS, Khorasgani MR, Roayaei M. Effects of Probiotics with or without
45 Honey on Radiation-induced Diarrhea. *International Journal of Radiation Research*
46 2016;14(3):205-13.

- 1 56. Garcia-Peris P, Velasco C, Lozano MA, et al. Effect of a mixture of inulin and fructo-
2 oligosaccharide on lactobacillus and bifidobacterium intestinal microbiota of patients
3 receiving radiotherapy; a randomised, double-blind, placebo-controlled trial. *Nutr*
4 *Hosp* 2012;27(6):1908-15.
- 5 57. Itoh Y, Mizuno M, Ikeda M, et al. A Randomized, Double-Blind Pilot Trial of Hydrolyzed
6 Rice Bran versus Placebo for Radioprotective Effect on Acute Gastroenteritis
7 Secondary to Chemoradiotherapy in Patients with Cervical Cancer. *Evid-Based Compl*
8 *Alt* 2015
- 9 58. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: Impact
10 of probiotics on diarrhea in patients treated with pelvic radiation. *Clin Nutr*
11 2014;33(5):761-67.
- 12 59. Chitapanarux I, Chitapanarux T, Traisathit P, et al. Randomized controlled trial of live
13 lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea
14 during radiotherapy in cervical cancer patients. *Radiat Oncol* 2010;5
- 15 60. Castro MG, Sanchez PX, Glasberg J, et al. Effects of probiotic in prevention of radiation-
16 induced diarrhea. *Clinical Nutrition Supplements* 2009;4(2):72-73.
- 17 61. Urbancsek H, Kazar T, Mezes I, et al. Results of a double-blind, randomized study to
18 evaluate the efficacy and safety of Antibiohilus (R) in patients with radiation-
19 induced diarrhoea. *Eur J Gastroen Hepat* 2001;13(4):391-96.
- 20 62. Murphy J, Stacey D, Crook J, et al. Testing control of radiation-induced diarrhea with a
21 psyllium bulking agent: a pilot study. *Can Oncol Nurs J* 2000;10(3):96-100.
- 22 63. Salminen E, Elomaa I, Minkkinen J, et al. Preservation of Intestinal Integrity during
23 Radiotherapy Using Live Lactobacillus-Acidophilus Cultures. *Clin Radiol*
24 1988;39(4):435-37.
- 25 64. Vidal-Casariago A, Calleja-Fernandez A, de Urbina-Gonzalez JJ, et al. Efficacy of
26 glutamine in the prevention of acute radiation enteritis: a randomized controlled
27 trial. *JPEN J Parenter Enteral Nutr* 2014;38(2):205-13.
- 28 65. Manir K, Kallol B, Gaurav K, et al. Role of glutamine versus placebo in prevention of
29 acute gastrointestinal toxicity in pelvic radiotherapy: A randomized control study. .
30 *Clinical Cancer Investigation Journal* 2014;3(6):508-13.
- 31 66. Kucuktulu E, Guner A, Kahraman I, et al. The protective effects of glutamine on
32 radiation-induced diarrhea. *Supportive Care in Cancer* 2013;21(4):1071-75.
- 33 67. Kozjek NR, Kompan L, Soeters P, et al. Oral glutamine supplementation during
34 preoperative radiochemotherapy in patients with rectal cancer: A randomised
35 double blinded, placebo controlled pilot study. *Clin Nutr* 2011;30(5):567-70.
- 36 68. Kozelsky TF, Meyers GE, Sloan JA, et al. Phase III double-blind study of glutamine versus
37 placebo for the prevention of acute diarrhea in patients receiving pelvic radiation
38 therapy. *J Clin Oncol* 2003;21(9):1669-74.
- 39 69. Faramarzi E, Mahdavi R, Mohammad-Zadeh M, et al. Effect of conjugated linoleic acid
40 supplementation on quality of life in rectal cancer patients undergoing preoperative
41 Chemoradiotherapy. *Pak J Med Sci* 2017;33(2):383-88.
- 42 70. Emami H, Nikoobin F, Roayaei M, et al. Double-blinded, randomized, placebo-controlled
43 study to evaluate the effectiveness of green tea in preventing acute gastrointestinal
44 complications due to radiotherapy. *J Res Med Sci* 2014;19(5):445-50.
- 45 71. Ahmad IU, Forman JD, Sarkar FH, et al. Soy Isoflavones in Conjunction With Radiation
46 Therapy in Patients With Prostate Cancer. *Nutr Cancer* 2010;62(7):996-1000.

- 1 72. Qiu G, Yu Y, Wang Y, et al. The significance of probiotics in preventing radiotherapy-
2 induced diarrhea in patients with cervical cancer: A systematic review and meta-
3 analysis. *Int J Surg* 2019;65:61-69.
- 4 73. Wei D, Heus P, van de Wetering FT, et al. Probiotics for the prevention or treatment of
5 chemotherapy- or radiotherapy-related diarrhoea in people with cancer. *Cochrane*
6 *Database Syst Rev* 2018;8:CD008831.
- 7 74. Liu MM, Li ST, Shu Y, et al. Probiotics for prevention of radiation-induced diarrhea: A
8 meta-analysis of randomized controlled trials. *PLoS One* 2017;12(6):e0178870.
- 9 75. Hamad A, Fragkos KC, Forbes A. A systematic review and meta-analysis of probiotics for
10 the management of radiation induced bowel disease. *Clinical Nutrition*
11 2013;32(3):353-60.
- 12 76. Fuccio L, Guido A, Eusebi LH, et al. Effects of Probiotics for the Prevention and
13 Treatment of Radiation-induced Diarrhea. *J Clin Gastroenterol* 2009;43(6):506-13.
14

1 **Figure legends**

2

3 **Figure 1** PRISMA flow chart of studies evaluated in the systematic review.

4

5 **Figure 2** Forest plot of effects of biotic, amino acid, PUFA and polyphenol supplements on
6 incidence of diarrhoea.

7

8 **Figure 3** Funnel plot for the meta-analysis that investigated the effect of dietary
9 supplements on incidence of diarrhoea.

10

11 **Figure 4** Forest plot of effect of prebiotic, probiotic and synbiotic supplements on incidence
12 of diarrhoea.

13

14 **Figure 5** Forest plot of effect of dietary supplements on incidence of moderate to severe
15 diarrhoea.

16


17 **Figure 6** Forest plot of effect of dietary supplements on incidence of anti-diarrhoeal
18 medication use.

19


20 **Figure 7** Schematic overview of potential benefits of dietary supplement intervention to
21 alleviate symptoms of gastrointestinal toxicity caused by pelvic radiotherapy.

22

23




1 **Figure 1**




1 **Figure 2**

2




1 **Figure 3**

2




1 **Figure 4**



1 **Figure 5**

2



1 **Figure 7**

2

1 Table 1 Characteristics of included studies

Study	Cancer type	Intervention	Sample size
Biotics			
Sasidharan, 2019 ⁵²	Cervical	Prebiotic: resistant starch	100
Linn, 2019 ⁵³	Cervical	Synbiotic: <i>L. acidophilus</i> , <i>B. animalis</i> and yoghurt	54
De Lorea-Rodriguez, 2018 ⁵⁴	Cervical	Synbiotic: <i>L. acidophilus</i> , <i>B. lactis</i> and insulin	70
Mansouri-Tehrani, 2016 ⁵⁵	Pelvic	Synbiotic: <i>S. thermophiles</i> , <i>Lactobacilli</i> , <i>Bifidobacter</i> and honey	46
Garcia-Peris, 2016 ⁵⁶	Gynaecological	Prebiotic: insulin oligosaccharide and fructo-oligosaccharide	38
Itoh, 2015 ⁵⁷	Cervical	Prebiotic: hydrolysed rice bran	20
Demers, 2014 ⁵⁸	Gynaecological, rectal or prostate	Probiotic: <i>L. acidophilus</i> and <i>B. longum</i>	148
Chitapanarux, 2010 ⁵⁹	Cervical	Probiotic: <i>L. acidophilus</i> and <i>B. bifidum</i>	63
Castro, 2010 ⁶⁰	Endometrial	Probiotic: <i>L. casei</i> and <i>B. breve</i>	40
Giralt, 2008 ³⁰	Cervical or endometrial	Synbiotic: <i>L. casei</i> , <i>S. thermophiles</i> and <i>L. delbrueckii</i>	85
Delia, 2007 ³⁴	Cervical or rectal	Probiotic: three strains of <i>bifidobacteria</i> and one strain of <i>streptococcus</i>	482
Urbancsek, 2001 ⁶¹	Pelvic	Probiotic: <i>L. rhamnosus</i>	205
Murphy, 2000 ⁶²	Gynaecological	Prebiotic: psyllium	60
Salminen, 1988 ⁶³	Gynaecological	Synbiotics: <i>L. acidophilus</i> and lactulose	21
Amino acids			
Vidal-Casariago, 2014 ⁶⁴	Pelvic	Glutamine	65
Manir, 2014 ⁶⁵	Pelvic	Glutamine	85
Kucuktulu, 2012 ⁶⁶	Rectal, bladder, prostate or gynaecological	Glutamine	36
Kozjek, 2011 ⁶⁷	Rectal cancer	Glutamine	33
Kozelsky, 2003 ⁶⁸	Gynaecological, rectal or prostate	Glutamine	129
PUFAs			
Aredes, 2019 ³⁶	Pelvic	EPA and DHA	42
Faramarzi, 2017 ⁶⁹	Rectal	CLA	26
Polyphenols			
Emami, 2014 ⁷⁰	Pelvic	Green tea	40
Ahmad, 2010 ⁷¹	Prostate	Soy isoflavones	31

2 All studies are RCTs

1 **Table 2 Meta-analyses of other gastrointestinal outcomes**

Outcome	Number of studies	Number of participants	Risk ratio (95% CI)	Test for overall effect, P	Heterogeneity I² (%; P value)
Incidence of vomiting	4	237	0.99 (0.79, 1.25)	0.95	59 (0.52)
Incidence of nausea	3	192	0.74 (0.36, 1.50)	0.40	0 (0.08)
Incidence of flatulence/bloating	3	152	1.12 (0.59, 2.12)	0.72	76 (0.01)
The mean number of bowel movements per day*	3	1045	-3.88 (-10.29, 2.52)	0.23	99 (<0.01)

2 *The outcome was mean difference.